Background
==========

Schizophrenia (SZ) is a severe brain disorder afflicting approximately 1% of the world\'s population and often leads to a lifetime of disability and emotional distress \[[@B1]\]. Family, twin, and adoption studies strongly indicate that genetics contribute to the etiology of SZ, probably by transmission of multiple susceptibility genes each exerting weak-to-moderate effects on predisposition \[[@B2],[@B3]\]. Many candidate susceptibility genes have been identified, including the dopamine receptor D2, neuregulin1, and disrupted in schizophrenia 1 (DISC-1) \[[@B4]-[@B6]\].

Epidemiological studies have also revealed that people with SZ are at greater risk for obesity, type 2 diabetes, dyslipidemia, and hypertension than the general population \[[@B7]\]. Recently, it was suggested that SZ patients are at increased risk of metabolic problems and that the associated symptoms are a serious threat to patient health \[[@B8]\]. Metabolic problems are often triggered by antipsychotic medication. Indeed, significant weight gain is common in AAP-treated SZ patients, especially patients administered clozapine, olanzapine, quetiapine, or risperidone \[[@B9]\].

The peptide ghrelin (product of the *GHRL*gene) is an important metabolic regulator produced by the stomach and pancreas. Specific SNPs of *GHRL*have been associated with variations in BMI, blood pressure, high-density lipoproteins, low-density lipoproteins, serum cholesterol, blood glucose, and metabolic syndrome \[[@B10]-[@B14]\]. Ghrelin, originally isolated from the rat stomach, stimulates food intake and controls energy balance \[[@B15],[@B16]\]. Studies on animal models revealed that *GHRL*increased food intake and adiposity \[[@B17],[@B18]\]. However, circulating *GHRL*levels were decreased in obese individuals, and serum *GHRL*levels were inversely correlated with BMI, suggesting that *GHRL*is not directly involved in most cases of obesity \[[@B19],[@B20]\]. Studies on the relationship between WG, circulating *GHRL*, and AAP have yielded inconsistent findings. Patients taking clozapine or olanzapine showed greater WG than patients on other antipsychotics \[[@B21]\]. In one study, plasma total *GHRL*and active *GHRL*were increased significantly immediately after olanzapine treatment, but the changes in BMI and body weight were not significant after 6 months of treatment \[[@B22]\]. In contrast, another study found that serum bioactive *GHRL*levels decreased significantly from baseline after 4 weeks of olanzapine monotherapy \[[@B23]\]. In humans, *GHRL*plays an important role in the long-term regulation of body weight (BW) as well as in the short-term regulation of appetite \[[@B19],[@B21]\]. Ghrelin stimulated preadipocyte differentiation, increased the BMI, and inhibited the anorexigenic effect of leptin \[[@B24]\]. Drug altering *GHRL*function may have distinct short- and long-term effects on BMI.

The human *GHRL*gene is located on chromosome 3 (3p25-p26), and consists of 4 exons and 3 introns \[[@B25],[@B26]\]. Several SNPs in the coding region of prepro-ghrelin have been described, but there is no known specific association between genetic variations in the human *GHRL*gene and SZ risk. However, region 3p25.1-26.1 is strongly associated with schizophrenia. In addition to *GHRL*, this region contains SYN2, HRH1, and GRM7, all candidate genes for schizophrenia. The positive symptoms of schizophrenia are associated with dysfunction in dopaminergic signaling, which is closely associated with a *GHRL*mutation \[[@B27]-[@B29]\]. Previous studies demonstrated that SNPs in *GHRL*were associated with high BMI; the Leu72Met allele was significantly associated with BMI and coronary artery disease \[[@B18],[@B19],[@B30]\], but this was not confirmed in other studies \[[@B26],[@B31],[@B32]\].

In light of the increase metabolic syndrome symptoms observed in SZ patients on AAPs, as well as the important role of *GHRL*as a metabolic regulator and the association between *GHRL*SNPs and metabolic indices, we hypothesized that (1) *GHRL*might be a candidate gene for SZ and that (2) allelic variants of *GHRL*might be associated with the propensity for BMI changes induced by AAP treatment. In addition, we tested (3) whether a putative relationship between *GHRL*SNPs and metabolic effects was specific to individual AAP types. Finally, (4) we examined if *GHRL*alleles influenced the clinical efficacy of AAPs. To these ends, we genotyped four SNPs and investigated whether they were associated with SZ and the therapeutic and metabolic effects of AAPs in the Han Chinese population.

Methods
=======

The study group consisted of 634 diagnosed schizophrenic patients (332 males and 302 females; mean age: 27.14 ± 7.53 years). Patients were unrelated Han Chinese born and living in the North Henan province, and all their biological grandparents were of Han Chinese ancestry. Individuals with a history of severe medical complications, organic brain disease, any concomitant major psychiatric disorders, or substance dependence were excluded. All patients were recruited from the Department of Psychiatry of the Second Affiliated Hospital of Xinxiang Medical University, P.R. China. The consensus diagnoses were conducted by at least two experienced psychiatrists according to the Diagnostic and Statistical Manual of Mental Disorders, fourth Edition (DSM-IV) \[[@B33]\]. The patient group included paranoid (n = 309), catatonic (n = 50), collapse (n = 45), residual (67), and undifferentiated (n = 163) schizophrenic types.

The control group consisted of 606 healthy subjects (293 males and 313 females; mean age: 29.08 ± 7.80 years) recruited from communities and colleges within the same region and matched to the patient group for age, gender ratio, and Han ethnicity. Controls were recruited using a simple non-structured interview performed by psychiatrists. Individuals with personal or family histories of mental illness or neurological diseases were excluded. The objectives and procedures of the study were explained to all subjects and written informed consent was obtained. The Ethical Committee of the Department of Psychiatry of the Second Affiliated Hospital of Xinxiang Medical University approved this study.

Three hundred and eighty patients were evaluated using the Positive and Negative Symptom Scale (PANSS) \[[@B34]\] before and after an 8-week administration of antipsychotic medications. Only those patients with total PANSS scores ≥ 60 before treatment were included. The reduction in PANSS scores from baseline after the 8-week treatment regime was used to evaluate the efficacy of each AAP. Patients were divided into 2 groups based on the reduction in PANSS score, a responder group exhibiting a \> 50% reduction and none-responder group exhibiting a ≤ 50% reduction \[[@B35]\].

We excluded patients with incomplete clinical data. A total of 569 patients were treated by monotherapy using an AAP not previously prescribed. Patients were treated with clozapine (n = 103, 100-700 mg/d), risperidone (n = 181, 2-6 mg/d), olanzapine (n = 60, 5-20 mg/d), quetiapine (n = 126, 400-750 mg/d), ziprasidone (n = 61, 80-160 mg/d), or aripiprazole (n = 38, 10-30 mg/d). Body weight and BMI was measured before and after 4 weeks of AAP treatment. Individual BMIs were calculated as BMI = weight (kg)/height^2^(m).

Peripheral blood samples were obtained from the subjects and genomic DNA was prepared using the QIAamp DNA blood Mini Kit (QIAGEN, Hilden, Germany). Four SNPs \[rs696217 (Leu72Met), rs26802 (-501A/C), rs27647 (-604 G/A), and rs26311 (-1062 G \> C)\] were selected according to the dbSNP database <http://www.ncbi.nlm.nih.gov/SNP/>. The SNPs rs27647 and rs26311 are located in the promoter region, rs26802 in intron 1, and rs696217 in exon 3 of *GHRL*. All these SNPs effect *GHRL*function and have been linked to metabolic symptoms. The rs696217 amino-acid change (Leu72Met) affects the tail of the pro-ghrelin molecule, but it is not known how this affects *GHRL*expression or activity (Table [1](#T1){ref-type="table"}). The four SNPs were detected by polymerase chain reaction (PCR)-based restriction fragment length polymorphism (PCR-RFLP) analysis.

###### 

SNPs and primers of PCRs and corresponding restriction enzymes

  Marker     Location   Primer sequence (5\'-3\')        Product (bp)   Annealing temperature (°C)   RFLP     Allele (bp)
  ---------- ---------- -------------------------------- -------------- ---------------------------- -------- ---------------
  rs27647    Promoter   5\'-CACAGCAACAAAGCTGCACC-3\'     929            65                           *Dra*I   A(929)
                        5\'-AAGTCCAGCCAGAGCATGCC-3\'                                                          G(664,265)
  rs26802    Intron 1   5\'-AGAACAAACGCCAGTCATCC-3\',    205            55                           *Mwo*I   A(205)
                        5\'-GTCTTCCAGCCAGACAGTCC-3\'                                                          C(104,101)
  rs696217   Exon 3     5\'-GCTGGGCTCCTACCTGAGC-3\'      618            65                           *Bsr*I   T(618)
                        5\'-GGACCCTGTTCACTGCCAC-3\'                                                           G(517,101)
  rs26311    Promoter   5\'-GGCAGCAGTCACGGACAATAAA-3\'   779            55                           *Bcn*I   G (572,252)
                        5\'-CTCAGAAGAGGCATCCGCTAAA-3\'                                                        C(527,191,61)

The primers of the four SNPs investigated are shown in Table [1](#T1){ref-type="table"}. The conditions used for PCR amplification included an initial denaturation step at 94°C for 5 min, followed by 36 cycles of 94°C for 30 s, 55-65°C for 30 s, and 72°C for 1 min, followed by a final extension at 72°C for 10 min. Small volumes (10 μl) of these PCR products were completely digested with 2U of restriction enzyme (*Dra I*for -604 G/A, *Mwo I*for -501A/C, *Bsr I*for Leu72Met, and *Bcn I*for -1062 G \> C). The fragments were separated on 2-4% agarose gels and visualized under ultraviolet light after staining with ethidium bromide.

The statistical power of the sample size was calculated by the genetic power calculator (GPC, <http://pngu.mgh.harvard.edu/~purcell/gpc/cc2.html>) \[[@B36]\]. Deviations in the genotype counts from Hardy-Weinberg equilibrium were tested using a *χ^2^*goodness-of-fit test. Statistical differences in genotypic, allelic, and haplotypic distributions between SZ and control subjects were evaluated by the *χ^2^*test with a significance level of 0.05. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated to evaluate the effects of different alleles on SZ risk. Pair-wise linkage disequilibrium (LD) analysis was applied to detect the inter-marker relationship using *D\'*and *r^2^*values. Case-control association analysis was performed by SHEsis software <http://analysis.bio-x.cn/myAnalysis.php>\[[@B37]\], a powerful software platform for analyses of LD, haplotype construction, and genetic association at polymorphic loci. Associations between response to a specific AAP and genotype were determined by *t*-tests and analysis of variance (ANOVA) tests using SPSS 13.0 software. Results were considered significant at *P*\< 0.05 (two-tailed).

The size of our sample was sufficient to detect a significant difference with a power of more than 70% assuming an OR value for AA of 1.5 with a minor allele frequency of 0.1 and type I error rate set at 0.05.

Results
=======

Four SNPs in the *GHRL*locus were analyzed: Leu72Met, -501A/C, -604 G/A, and -1062 G \> C. As shown in Table [2](#T2){ref-type="table"}, none of the genotype distributions of these four SNPs showed significant deviation from Hardy-Weinberg equilibrium, and none of the allele frequencies or the genotype distribution differed between patients and controls (*P*\> 0.05). There was also no significant association between any allele or genotype and SZ when patients were subdivided by gender (Table [3](#T3){ref-type="table"}).

###### 

Genotype and allele frequencies of four SNPs in *GHRL*gene between schizophrenia patients and healthy controls

  Marker     N ^a^   Genotype ^b^   HWE          *P*-value    Allele ^b^   *P*-value   OR^c^(95%CI)                         
  ---------- ------- -------------- ------------ ------------ ------------ ----------- -------------- ------------- ------- -----------------
  rs696217           GG             GT           TT                                    G              T                     
  Patients   634     427(0.684)     180(0.288)   17(0.027)    0.704        0.649       1034(0.829)    214(0.171)    0.773   1.03(0.83-1.27)
  Controls   606     400(0.670)     184(0.308)   13(0.022)    0.123                    984(0.824)     210(0.176)            
  rs26802            AA             AC           CC                                    A              C                     
  Patients   634     534(0.842)     95(0.150)    5(0.008)     0.732        0.944       1163(0.917)    105(0.083)    0.922   1.01(0.76-1.35)
  Controls   606     505(0.839)     93(0.154)    4(0.007)     0.900                    1103(0.916)    101(0.084)            
  rs27647            AA             AG           GG                                    A              G                     
  Patients   634     10(0.016)      133(0.210)   491(0.774)   0.773        0.410       153(0.121)     1115(0.879)   0.301   1.13(0.88-1.46)
  Controls   606     5(0.008)       120(0.198)   480(0.793)   0.400                    130(0.107)     1080(0.893)           
  rs26311            CC             CG           GG                                    C              G                     
  Patients   634     253(0.402)     298(0.474)   78(0.124)    0.498        0.826       804(0.639)     454(0.361)    0.723   1.03(0.87-1.21)
  Controls   606     234(0.387)     297(0.491)   74(0.122)    0.171                    765(0.632)     445(0.368)            

^a^Number of samples which are well genotyped

^b^Frequencies are shown in parenthesis

^c^Odds ratios of alleles were calculated for each reference *vs*. variant allele

###### 

Genotype frequencies of the four SNPs interaction with gender

  dbSNP ID   Genotype   Female   Male                       
  ---------- ---------- -------- ------ ------- ----- ----- -------
  rs696217   GG         224      191    0.689   203   209   0.896
             GT         93       91             87    93    
             TT         11       7              6     6     
  rs26802    AA         279      247    0.306   255   258   0.723
             AC         50       41             45    52    
             CC         3        2              2     2     
  rs27647    AA         4        2      0.151   6     3     0.368
             AG         77       51             56    69    
             GG         251      240            240   240   
  rs26311    CC         142      118    0.358   111   116   0.876
             CG         150      139            148   158   
             GG         37       36             41    38    

To further analyze the haplotype structure in our sample, pair-wise linkage disequilibrium (LD) of the four SNPs in the control group was computed using the standardized measures *D*\' and *r*^2^values. There was strong LD in Leu72Met and -501A/C, so haplotype analyses were performed (Table [4](#T4){ref-type="table"}). However, the haplotypes constructed from two SNPs showed no significant differences between patients and controls (Table [5](#T5){ref-type="table"}).

###### 

Pairwise linkage disequilibrium among four SNPs in the *GHRL*gene *(D*\' values is shown above and r^2^values below the diagonal)

             rs696217   rs26802     rs27647   rs26311
  ---------- ---------- ----------- --------- ---------
  rs696217              **0.901**   0.004     0.261
  rs26802    0.016                  0.175     0.193
  rs27647    0.000      0.000                 0.116
  rs26311    0.025      0.006       0.001     

###### 

Estimated haplotype frequencies and case-control haplotype results

  SNP                      Haplotype   Frequencies     *χ^2^*          *P*-value   OR (95%CI)   Global                        
  ------------------------ ----------- --------------- --------------- ----------- ------------ --------------------- ------- -------
  **rs696217\--rs26802**   G-A         930.15(0.745)   883.02(0.742)   0.007       0.933        1.008(0.840\~1.209)   0.022   0.989
                           G-C         103.85(0.083)   97.98(0.082)    0.004       0.952        1.009(0.756\~1.346)           
                           T-A         213.85(0.171)   205.98(0.173)   0.020       0.888        0.985(0.798\~1.216)           

Of the 634 patients with SZ, 380 completed the PANSS to assess psychopathological syndromes. The results revealed that there were no significant differences in PANSS score reduction among the different genotypes of the four SNPs (-604 G/A, -501A/C, Leu72Met and -1062 G \> C) after 8 weeks treatment with AAPs (Table [6](#T6){ref-type="table"}). However, in the responder group with the larger decreases in PANSS scores (\> 50%), there was a significant association between BW and BMI increase (Table [7](#T7){ref-type="table"}). The responder group exhibited significantly greater BW and BMI increases than none responders, and patients in specific AAP treatment groups with high weight gain showed greater improvements than those with low weight gain when subdivided according to drug (Table [8](#T8){ref-type="table"}).

###### 

Reduction of PANSS scores in patients with different GHRL genotypes ($\overset{-}{x} \pm s$)

  SNP        Genotype   N     Before treatment   After 8 weeks treatment   Reduction rate (%)\*                                                                                
  ---------- ---------- ----- ------------------ ------------------------- ---------------------- --------------- --------------- -------------- -------------- -------------- -------------
  rs27647    GG         292   88.06 ± 21.64      24.49 ± 6.63              21.46 ± 8.00           42.11 ± 12.34   45.84 ± 12.63   10.87 ± 3.69   11.65 ± 4.85   23.32 ± 6.33   0.72 ± 0.19
             GA+AA      88    87.38 ± 23.51      23.05 ± 6.92              22.81 ± 8.28           41.52 ± 13.4    45.40 ± 10.86   10.68 ± 3.53   12.24 ± 5.05   22.48 ± 4.88   0.72 ± 0.19
             *P*              0.799              0.076                     0.169                  0.702           0.767           0.672          0.321          0.250          0.988
  rs26802    AA         322   88.61 ± 22.47      24.35 ± 6.80              21.74 ± 8.26           42.52 ± 12.76   45.91 ± 12.47   10.90 ± 3.76   11.76 ± 4.97   23.25 ± 6.17   0.72 ± 0.19
             AC+CC      58    83.97 ± 19.33      23.09 ± 6.16              21.91 ± 7.00           38.97 ± 11.20   44.79 ± 10.85   10.43 ± 2.96   11.93 ± 4.49   22.43 ± 5.15   0.72 ± 0.18
             *P*              0.140              0.187                     0.882                  0.048           0.524           0.371          0.805          0.341          0.929
  rs696217   GG         253   87.91 ± 22.94      24.23 ± 6.53              21.66 ± 8.36           42.02 ± 13.15   45.09 ± 11.31   10.63 ± 3.60   11.61 ± 4.70   22.85 ± 5.34   0.73 ± 0.18
             GT+TT      120   87.65 ± 19.38      24.11 ± 6.96              21.82 ± 7.36           41.73 ± 10.91   45.97 ± 11.41   11.01 ± 3.31   11.74 ± 4.70   23.22 ± 6.10   0.71 ± 0.20
             *P*              0.915              0.870                     0.864                  0.834           0.484           0.329          0.798          0.555          0.309
  rs26311    CC         153   87.25 ± 22.59      24.09 ± 6.84              21.58 ± 7.52           41.58 ± 13.06   45.30 ± 11.10   10.85 ± 3.70   11.52 ± 4.52   22.93 ± 5.35   0.72 ± 0.19
             GG+GC      223   87.66 ± 21.04      24.09 ± 6.59              21.74 ± 8.36           41.83 ± 11.82   46.01 ± 13.04   10.79 ± 3.63   11.96 ± 5.15   23.25 ± 6.49   0.72 ± 0.19
             *P*              0.857              0.998                     0.845                  0.848           0.582           0.884          0.385          0.619          0.883

\*reduction rates of PANSS total scores; \*\* total scores; ^a^Positive score; ^b^negative score; ^c^general pathology score

###### 

The BW and BMI change in responder group and none-responder groups

  Two group ^a^          N     BW change ^b^($\overset{-}{x} \pm s$) kg   BMI change ^c^($\overset{-}{x} \pm s$)
  ---------------------- ----- ------------------------------------------ ----------------------------------------
  responder group        339   0.68 ± 4.00                                0.27 ± 1.47
  none-responder group   41    -1.13 ± 2.35                               -0.42 ± 0.87
                                                                          
  P-value                      0.000                                      0.000

^a^Patients were divided into 2 groups based on reduction rates of PANSS total scores, namely, responder group (\> 50%) and none-responder group (≤ 50%)

^b^Body weight change = body weight (4-week) - body weight(0 week)

^c^BMI change = BMI (4-week) - BMI (0 week)

###### 

The BW and BMI change in responder group and none-responder groups when subdivided according to different AAPs ($\overset{-}{x} \pm s$)

  Two groups ^a^         AAP ^b^        N     BW change (kg)   P-value     BMI change     P-value
  ---------------------- -------------- ----- ---------------- ----------- -------------- -----------
  responder group        clozapine      63    0.60 ± 3.94      **0.012**   0.21 ± 1.41    **0.009**
                         risperidone    115   1.20 ± 3.71                  0.46 ± 1.41    
                         olanzapine     25    1.94 ± 4.47                  0.76 ± 1.68    
                         quetiapine     76    1.01 ± 3.41                  0.37 ± 1.26    
                         ziprasidone    32    -1.66 ± 4.78                 -0.60 ± 1.74   
                         aripiprazole   26    -0.67 ± 4.42                 -0.19 ± 1.49   
  none-responder group   clozapine      7     -1.57 ± 2.30     0.917       -0.55 ± 0.80   0.834
                         risperidone    11    -1.18 ± 1.99                 -0.47 ± 0.79   
                         olanzapine     5     -0.60 ± 1.82                 -0.18 ± 0.62   
                         quetiapine     8     -0.44 ± 2.87                 -0.16 ± 1.07   
                         ziprasidone    6     -1.5 ± 2.74                  -0.56 ± 0.95   
                         aripiprazole   3     -1.8 ± 3.69                  -0.73 ± 1.42   

^a^responder group and none-responder group

^b^atypical antipsychotics

The main clinical and biochemical characteristics of the schizophrenic patients were analyzed with nonparametric tests. There was a significant association between BW and BMI measured before and after 4-week AAP treatment (*P*= 0.005 and 0.004 respectively). Patients with the -604 G/A exhibited significantly higher BWs and BMIs after treatment (*P*= 0.028 and 0.011, respectively) (Table [9](#T9){ref-type="table"}). Similarly, paranoid SZ patients (n = 309) demonstrated greater WG and BMI increases (*P*= 0.020 and 0.011, respectively). In addition, there were significant differences in the BW and BMI increases between G allele carriers and homozygous allele A carriers in patients harboring SNP-604 G/A (*P*= 0.039 and 0.013, respectively).

###### 

The association analysis of BW and BMI in four SNPs

  SNP        Genotype    BW(0 week, kg)   BW(4 week, kg)   BW change (kg)   BMI(0 week)    BMI(4 week)    BMI change
  ---------- ----------- ---------------- ---------------- ---------------- -------------- -------------- --------------
  rs27647    GG          62.69 ± 11.86    63.16 ± 11.19    0.55 ± 3.85      22.65 ± 3.60   22.84 ± 3.44   0.21 ± 1.42
             AG          62.85 ± 12.44    62.87 ± 11.88    -0.18 ± 3.35     22.16 ± 3.59   22.13 ± 3.48   -0.04 ± 1.18
             AA          58.4 ± 7.40      61.39 ± 10.25    2.61 ± 3.46      21.4 ± 2.91    23.05 ± 3.71   1.15 ± 1.21
             *P-*value   0.426            0.810            **0.028**\*      0.392          0.181          **0.011**\*
  rs26802    AA          62.53 ± 12.13    62.90 ± 11.33    0.40 ± 3.79      22.54 ± 3.62   22.68 ± 3.45   0.17 ± 1.39
             AC          63.35 ± 10.90    64.40 ± 11.28    0.87 ± 3.36      22.51 ± 3.54   22.95 ± 3.55   0.30 ± 1.21
             CC          59.70 ± 9.78     56.8 ± 6.30      -2.9 ± 6.07      21.66 ± 2.03   20.68 ± 1.28   -0.97 ± 2.17
             *P-*value   0.572            0.163            0.247            0.839          0.275          0.269
  rs696217   GG          62.16 ± 11.75    62.77 ± 11.29    0.62 ± 3.60      22.33 ± 3.45   22.58 ± 3.37   0.24 ± 1.30
             GT          63.57 ± 12.05    63.67 ± 11.08    0.10 ± 3.85      22.83 ± 3.57   22.86 ± 3.34   0.05 ± 1.41
             TT          63.75 ± 15.14    63.67 ± 14.83    -0.08 ± 6.49     23.60 ± 6.07   23.60 ± 6.08   0.002 ± 2.51
             *P-*value   0.446            0.589            0.319            0.358          0.676          0.254
  rs26311    GG          63.30 ± 12.10    63.09 ± 10.36    0.41 ± 3.39      23.13 ± 3.74   23.12 ± 3.43   0.15 ± 1.28
             GC          62.29 ± 12.25    62.89 ± 11.32    0.49 ± 3.90      22.63 ± 3.75   22.86 ± 3.48   0.20 ± 1.43
             CC          62.77 ± 11.52    63.24 ± 11.65    0.41 ± 3.71      22.21 ± 3.34   22.39 ± 3.44   0.16 ± 1.34
             *P-*value   0.792            0.925            0.804            0.343          0.344          0.765

Discussion
==========

The associations between *GHRL*polymorphisms and SZ risk, changes in weight/BMI, and therapeutic responses to AAPs were evaluated in a population of SZ patients of Han Chinese ethnicity. While we found no association between *GHRL*gene polymorphisms and SZ susceptibility in this case-control study, analysis did reveal significant BW and BMI increases during AAP treatment in patients harboring the -604 G/A polymorphism.

To our knowledge, no previous study has examined the association between *GHRL*gene polymorphisms and susceptibility to SZ. Our study revealed no significant differences in allele and genotype frequency of four *GHRL*SNPs between schizophrenic patients and controls even when patients were subdivided by gender. Thus, *GHRL*is not a likely SZ risk gene despite the fact that it is in a susceptibility locus (3p25-p26). Furthermore, we also examined paranoid SZ cases in light of the study by Scassellati et al. \[[@B38]\]. Again, we found no significant differences in the frequency of these four SNPs or the genotype distribution between paranoid patients and controls, but this could reflect the relatively small sample size of paranoid schizophrenic patients in our cohort. Furthermore, we found no haplotypes with significantly higher frequency between cases and controls. Therefore, we suggest that *GHRL*is not a predisposing gene for SZ in the Chinese Han population.

In the present study, no association between PANSS reduction during AAP treatment and *GHRL*gene polymorphisms was found. However, the magnitude of the PANSS score reduction was significantly associated with the increase in BW and BMI during AAP treatment. Meanwhile, the reduction rate of PANSS total score in responder and none-responder groups had significant association with BW and BMI increase. The same finding was also revealed when patients were subdivided according the specific AAP taken. Atypical antipsychotics induced weight gain in a significant fraction of SZ patients \[[@B9]\], but factors that are predictive of weight gain during AAP therapy are unclear. We found that patients exhibiting the greatest weight gains while receiving olanzapine, risperidone, clozapine, or quetiapine also showed greater improvements in symptoms than those showing lower weight gain. This result is in partial accord with a previous study that found olanzapine-induced weight gain correlated negatively with baseline BMI and positively with clinical global improvement and the length of olanzapine treatment \[[@B39]\].

The *GHRL*gene may be a promising candidate underlying AP-induced weight gain \[[@B40]\]. We found significant differences between the three -604 G/A genotypes, with patients harboring AA showing the greatest weight gain and increase in BMI. In addition to BMI, -604 G/A has been linked to variations in blood pressure \[[@B12]\]. Previous studies have also reported that the Leu72Met polymorphism was significantly associated with BMI \[[@B10],[@B11]\]. However, we found no association between Leu72Met polymorphisms and the AAP-induced BMI increase, consistent with previous findings \[[@B26],[@B31],[@B32]\]. In addition to the significant association between the AA genotype and BMI, we also found that paranoid SZ patients demonstrated higher weight gain than patients with other subtypes of SZ, including catatonic, collapse, residual, and undifferentiated patients. Therefore, our results provide suggestive evidence for a link between -604 G/A and metabolic syndrome in paranoid SZ.

Conclusion
==========

While we did not find an association between *GHRL*alleles and susceptibility to SZ in the Chinese Han population, the -604 G/A polymorphism, and particularly the AA genotype, was associated with larger increases in BW and BMI in SZ patients under treatment with AAPs. Surprisingly, patients showing the greatest weight gain also showed the greatest improvements in symptoms. In order to more precisely define the impact of antipsychotic medications on metabolic parameters, control of patient subtype, sample size, as well as monitoring of multiple metabolic indices during antipsychotic therapy are of paramount importance.
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